25 XP   0   0   10

StageZero Life Sciences Ltd
Buy, Hold or Sell?

Let's analyse StageZero Life Sciences Ltd together

PenkeI guess you are interested in StageZero Life Sciences Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of StageZero Life Sciences Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about StageZero Life Sciences Ltd

I send you an email if I find something interesting about StageZero Life Sciences Ltd.

Quick analysis of StageZero Life Sciences Ltd (30 sec.)










What can you expect buying and holding a share of StageZero Life Sciences Ltd? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$-0.08
Expected worth in 1 year
C$-0.54
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
C$-0.46
Return On Investment
-1,145.8%

For what price can you sell your share?

Current Price per Share
C$0.04
Expected price per share
C$0.04 - C$0.05
How sure are you?
50%

1. Valuation of StageZero Life Sciences Ltd (5 min.)




Live pricePrice per Share (EOD)

C$0.04

Intrinsic Value Per Share

C$-0.41 - C$-0.19

Total Value Per Share

C$-0.49 - C$-0.27

2. Growth of StageZero Life Sciences Ltd (5 min.)




Is StageZero Life Sciences Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?-$7.5m$2.7m-$10.2m-136.8%

How much money is StageZero Life Sciences Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$14.7m-$6.6m-$8m-54.9%
Net Profit Margin-387.7%-130.9%--

How much money comes from the company's main activities?

3. Financial Health of StageZero Life Sciences Ltd (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#136 / 145

Most Revenue
#114 / 145

Most Profit
#118 / 145

Most Efficient
#126 / 145

What can you expect buying and holding a share of StageZero Life Sciences Ltd? (5 min.)

Welcome investor! StageZero Life Sciences Ltd's management wants to use your money to grow the business. In return you get a share of StageZero Life Sciences Ltd.

What can you expect buying and holding a share of StageZero Life Sciences Ltd?

First you should know what it really means to hold a share of StageZero Life Sciences Ltd. And how you can make/lose money.

Speculation

The Price per Share of StageZero Life Sciences Ltd is C$0.04. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of StageZero Life Sciences Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in StageZero Life Sciences Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$-0.08. Based on the TTM, the Book Value Change Per Share is C$-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is C$0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of StageZero Life Sciences Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps-0.09-232.6%-0.09-232.6%-0.06-152.5%-0.05-134.2%-0.06-141.8%
Usd Book Value Change Per Share-0.08-209.1%-0.08-209.1%0.0381.4%-0.01-18.3%-0.01-25.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.08-209.1%-0.08-209.1%0.0381.4%-0.01-18.3%-0.01-25.6%
Usd Price Per Share0.04-0.04-0.22-0.18-0.32-
Price to Earnings Ratio-0.47--0.47--3.59--3.27--4.97-
Price-to-Total Gains Ratio-0.52--0.52-6.73-7.47-39.96-
Price to Book Ratio-0.72--0.72-9.73--9.48-5.48-
Price-to-Total Gains Ratio-0.52--0.52-6.73-7.47-39.96-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.029204
Number of shares34241
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.08-0.01
Usd Total Gains Per Share-0.08-0.01
Gains per Quarter (34241 shares)-2,864.47-250.45
Gains per Year (34241 shares)-11,457.89-1,001.82
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-11458-114680-1002-1012
20-22916-229260-2004-2014
30-34374-343840-3005-3016
40-45832-458420-4007-4018
50-57289-573000-5009-5020
60-68747-687580-6011-6022
70-80205-802160-7013-7024
80-91663-916740-8015-8026
90-103121-1031320-9016-9028
100-114579-1145900-10018-10030

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.025.00.00.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%12.013.00.048.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.025.00.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%12.013.00.048.0%

Fundamentals of StageZero Life Sciences Ltd

About StageZero Life Sciences Ltd

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

Fundamental data was last updated by Penke on 2024-04-03 22:03:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of StageZero Life Sciences Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit StageZero Life Sciences Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare StageZero Life Sciences Ltd to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -387.7% means that $-3.88 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of StageZero Life Sciences Ltd:

  • The MRQ is -387.7%. The company is making a huge loss. -2
  • The TTM is -387.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-387.7%TTM-387.7%0.0%
TTM-387.7%YOY-130.9%-256.7%
TTM-387.7%5Y-560.1%+172.4%
5Y-560.1%10Y-1,481.6%+921.5%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-387.7%-7.7%-380.0%
TTM-387.7%-6.7%-381.0%
YOY-130.9%2.4%-133.3%
5Y-560.1%-1.5%-558.6%
10Y-1,481.6%-3.4%-1,478.2%
1.1.2. Return on Assets

Shows how efficient StageZero Life Sciences Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare StageZero Life Sciences Ltd to the Diagnostics & Research industry mean.
  • -2,099.8% Return on Assets means that StageZero Life Sciences Ltd generated $-21.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of StageZero Life Sciences Ltd:

  • The MRQ is -2,099.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2,099.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2,099.8%TTM-2,099.8%0.0%
TTM-2,099.8%YOY-62.3%-2,037.5%
TTM-2,099.8%5Y-485.3%-1,614.6%
5Y-485.3%10Y-446.8%-38.4%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,099.8%-1.7%-2,098.1%
TTM-2,099.8%-1.3%-2,098.5%
YOY-62.3%-0.9%-61.4%
5Y-485.3%-0.5%-484.8%
10Y-446.8%-0.9%-445.9%
1.1.3. Return on Equity

Shows how efficient StageZero Life Sciences Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare StageZero Life Sciences Ltd to the Diagnostics & Research industry mean.
  • 0.0% Return on Equity means StageZero Life Sciences Ltd generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of StageZero Life Sciences Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-240.3%+240.3%
TTM-5Y-48.1%+48.1%
5Y-48.1%10Y-136.9%+88.8%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ--0.7%+0.7%
TTM--0.1%+0.1%
YOY-240.3%0.3%-240.6%
5Y-48.1%-1.4%-46.7%
10Y-136.9%-2.3%-134.6%

1.2. Operating Efficiency of StageZero Life Sciences Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient StageZero Life Sciences Ltd is operating .

  • Measures how much profit StageZero Life Sciences Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare StageZero Life Sciences Ltd to the Diagnostics & Research industry mean.
  • An Operating Margin of -204.1% means the company generated $-2.04  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of StageZero Life Sciences Ltd:

  • The MRQ is -204.1%. The company is operating very inefficient. -2
  • The TTM is -204.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-204.1%TTM-204.1%0.0%
TTM-204.1%YOY-160.4%-43.7%
TTM-204.1%5Y-1,296.6%+1,092.5%
5Y-1,296.6%10Y-1,392.1%+95.5%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-204.1%-6.2%-197.9%
TTM-204.1%0.5%-204.6%
YOY-160.4%4.3%-164.7%
5Y-1,296.6%3.7%-1,300.3%
10Y-1,392.1%-1.3%-1,390.8%
1.2.2. Operating Ratio

Measures how efficient StageZero Life Sciences Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 3.06 means that the operating costs are $3.06 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of StageZero Life Sciences Ltd:

  • The MRQ is 3.064. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.064. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.064TTM3.0640.000
TTM3.064YOY2.604+0.460
TTM3.0645Y14.006-10.942
5Y14.00610Y14.267-0.261
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0641.296+1.768
TTM3.0641.301+1.763
YOY2.6041.238+1.366
5Y14.0061.268+12.738
10Y14.2671.217+13.050

1.3. Liquidity of StageZero Life Sciences Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if StageZero Life Sciences Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 0.04 means the company has $0.04 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of StageZero Life Sciences Ltd:

  • The MRQ is 0.038. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.038. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.038TTM0.0380.000
TTM0.038YOY0.503-0.465
TTM0.0385Y0.390-0.352
5Y0.39010Y0.853-0.463
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0382.111-2.073
TTM0.0382.298-2.260
YOY0.5032.581-2.078
5Y0.3903.012-2.622
10Y0.8533.081-2.228
1.3.2. Quick Ratio

Measures if StageZero Life Sciences Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare StageZero Life Sciences Ltd to the Diagnostics & Research industry mean.
  • A Quick Ratio of 0.01 means the company can pay off $0.01 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of StageZero Life Sciences Ltd:

  • The MRQ is 0.007. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.007. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.007TTM0.0070.000
TTM0.007YOY0.390-0.384
TTM0.0075Y0.332-0.325
5Y0.33210Y0.797-0.465
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0071.204-1.197
TTM0.0071.285-1.278
YOY0.3901.565-1.175
5Y0.3321.925-1.593
10Y0.7972.128-1.331

1.4. Solvency of StageZero Life Sciences Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of StageZero Life Sciences Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare StageZero Life Sciences Ltd to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 11.71 means that StageZero Life Sciences Ltd assets are financed with 1,170.9% credit (debt) and the remaining percentage (100% - 1,170.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of StageZero Life Sciences Ltd:

  • The MRQ is 11.709. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 11.709. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ11.709TTM11.7090.000
TTM11.709YOY0.741+10.968
TTM11.7095Y3.965+7.744
5Y3.96510Y2.910+1.055
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ11.7090.421+11.288
TTM11.7090.407+11.302
YOY0.7410.394+0.347
5Y3.9650.448+3.517
10Y2.9100.446+2.464
1.4.2. Debt to Equity Ratio

Measures if StageZero Life Sciences Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare StageZero Life Sciences Ltd to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of StageZero Life Sciences Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.855-2.855
TTM-5Y0.571-0.571
5Y0.57110Y0.393+0.178
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.606-0.606
TTM-0.567-0.567
YOY2.8550.631+2.224
5Y0.5710.658-0.087
10Y0.3930.742-0.349

2. Market Valuation of StageZero Life Sciences Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings StageZero Life Sciences Ltd generates.

  • Above 15 is considered overpriced but always compare StageZero Life Sciences Ltd to the Diagnostics & Research industry mean.
  • A PE ratio of -0.47 means the investor is paying $-0.47 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of StageZero Life Sciences Ltd:

  • The EOD is -0.314. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.471. Based on the earnings, the company is expensive. -2
  • The TTM is -0.471. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.314MRQ-0.471+0.157
MRQ-0.471TTM-0.4710.000
TTM-0.471YOY-3.591+3.120
TTM-0.4715Y-3.270+2.799
5Y-3.27010Y-4.971+1.701
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.314-0.261-0.053
MRQ-0.471-0.409-0.062
TTM-0.471-0.341-0.130
YOY-3.5910.002-3.593
5Y-3.2704.832-8.102
10Y-4.9715.198-10.169
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of StageZero Life Sciences Ltd:

  • The EOD is -1.016. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.523. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.523. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.016MRQ-1.523+0.508
MRQ-1.523TTM-1.5230.000
TTM-1.523YOY-2.952+1.429
TTM-1.5235Y-5.645+4.121
5Y-5.64510Y-16.062+10.418
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-1.016-0.291-0.725
MRQ-1.523-0.441-1.082
TTM-1.523-1.388-0.135
YOY-2.952-2.079-0.873
5Y-5.645-1.446-4.199
10Y-16.062-1.971-14.091
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of StageZero Life Sciences Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of -0.72 means the investor is paying $-0.72 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of StageZero Life Sciences Ltd:

  • The EOD is -0.478. Based on the equity, the company is expensive. -2
  • The MRQ is -0.716. Based on the equity, the company is expensive. -2
  • The TTM is -0.716. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.478MRQ-0.716+0.239
MRQ-0.716TTM-0.7160.000
TTM-0.716YOY9.732-10.448
TTM-0.7165Y-9.476+8.760
5Y-9.47610Y5.477-14.953
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.4781.857-2.335
MRQ-0.7162.228-2.944
TTM-0.7162.222-2.938
YOY9.7323.104+6.628
5Y-9.4763.447-12.923
10Y5.4774.036+1.441
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of StageZero Life Sciences Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.115-0.1150%0.045-357%-0.010-91%-0.014-88%
Book Value Per Share---0.084-0.0840%0.031-372%-0.034-59%-0.023-72%
Current Ratio--0.0380.0380%0.503-92%0.390-90%0.853-96%
Debt To Asset Ratio--11.70911.7090%0.741+1481%3.965+195%2.910+302%
Debt To Equity Ratio----0%2.855-100%0.571-100%0.393-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.127-0.1270%-0.084-34%-0.074-42%-0.078-39%
Free Cash Flow Per Share---0.039-0.0390%-0.102+158%-0.053+34%-0.044+11%
Free Cash Flow To Equity Per Share---0.019-0.0190%-0.056+195%0.000-98%-0.001-96%
Gross Profit Margin--1.0511.0510%1.187-12%1.048+0%1.049+0%
Intrinsic Value_10Y_max---0.190--------
Intrinsic Value_10Y_min---0.410--------
Intrinsic Value_1Y_max---0.039--------
Intrinsic Value_1Y_min---0.055--------
Intrinsic Value_3Y_max---0.101--------
Intrinsic Value_3Y_min---0.154--------
Intrinsic Value_5Y_max---0.146--------
Intrinsic Value_5Y_min---0.240--------
Market Cap4908680.000-50%7363020.0007363020.0000%36815100.000-80%29697514.000-75%53750046.000-86%
Net Profit Margin---3.877-3.8770%-1.309-66%-5.601+44%-14.816+282%
Operating Margin---2.041-2.0410%-1.604-21%-12.966+535%-13.921+582%
Operating Ratio--3.0643.0640%2.604+18%14.006-78%14.267-79%
Pb Ratio-0.478+33%-0.716-0.7160%9.732-107%-9.476+1223%5.477-113%
Pe Ratio-0.314+33%-0.471-0.4710%-3.591+663%-3.270+594%-4.971+956%
Price Per Share0.040-50%0.0600.0600%0.300-80%0.242-75%0.438-86%
Price To Free Cash Flow Ratio-1.016+33%-1.523-1.5230%-2.952+94%-5.645+271%-16.062+954%
Price To Total Gains Ratio-0.349+33%-0.524-0.5240%6.727-108%7.466-107%39.963-101%
Quick Ratio--0.0070.0070%0.390-98%0.332-98%0.797-99%
Return On Assets---20.998-20.9980%-0.623-97%-4.853-77%-4.468-79%
Return On Equity----0%-2.4030%-0.4810%-1.3690%
Total Gains Per Share---0.115-0.1150%0.045-357%-0.010-91%-0.014-88%
Usd Book Value---7504019.654-7504019.6540%2762016.265-372%-3060921.657-59%-2092372.675-72%
Usd Book Value Change Per Share---0.084-0.0840%0.033-357%-0.007-91%-0.010-88%
Usd Book Value Per Share---0.061-0.0610%0.023-372%-0.025-59%-0.017-72%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.093-0.0930%-0.061-34%-0.054-42%-0.057-39%
Usd Free Cash Flow---3529077.046-3529077.0460%-9103916.199+158%-4739946.801+34%-3934465.206+11%
Usd Free Cash Flow Per Share---0.029-0.0290%-0.074+158%-0.039+34%-0.032+11%
Usd Free Cash Flow To Equity Per Share---0.014-0.0140%-0.041+195%0.000-98%-0.001-96%
Usd Market Cap3583827.268-50%5375740.9025375740.9020%26878704.510-80%21682154.971-75%39242908.585-86%
Usd Price Per Share0.029-50%0.0440.0440%0.219-80%0.177-75%0.320-86%
Usd Profit---14713819.542-14713819.5420%-6637289.806-55%-6902256.110-53%-7058387.795-52%
Usd Revenue--3795421.2763795421.2760%5068617.101-25%2668166.728+42%1736953.056+119%
Usd Total Gains Per Share---0.084-0.0840%0.033-357%-0.007-91%-0.010-88%
 EOD+2 -6MRQTTM+0 -0YOY+8 -255Y+10 -2310Y+11 -22

3.2. Fundamental Score

Let's check the fundamental score of StageZero Life Sciences Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.314
Price to Book Ratio (EOD)Between0-1-0.478
Net Profit Margin (MRQ)Greater than0-3.877
Operating Margin (MRQ)Greater than0-2.041
Quick Ratio (MRQ)Greater than10.007
Current Ratio (MRQ)Greater than10.038
Debt to Asset Ratio (MRQ)Less than111.709
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-20.998
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of StageZero Life Sciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.221
Ma 20Greater thanMa 500.044
Ma 50Greater thanMa 1000.044
Ma 100Greater thanMa 2000.046
OpenGreater thanClose0.040
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Long-term Assets Other  34916950-91634034-340



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets701
Total Liabilities8,204
Total Stockholder Equity-7,503
 As reported
Total Liabilities 8,204
Total Stockholder Equity+ -7,503
Total Assets = 701

Assets

Total Assets701
Total Current Assets266
Long-term Assets434
Total Current Assets
Cash And Cash Equivalents 16
Net Receivables 31
Inventory 96
Other Current Assets 124
Total Current Assets  (as reported)266
Total Current Assets  (calculated)266
+/-0
Long-term Assets
Property Plant Equipment 434
Long-term Assets Other 0
Long-term Assets  (as reported)434
Long-term Assets  (calculated)434
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,026
Long-term Liabilities1,178
Total Stockholder Equity-7,503
Total Current Liabilities
Short-term Debt 1,224
Short Long Term Debt 1,030
Accounts payable 2,821
Other Current Liabilities 2,912
Total Current Liabilities  (as reported)7,026
Total Current Liabilities  (calculated)7,987
+/- 961
Long-term Liabilities
Long term Debt Total 576
Long term Debt 576
Capital Lease Obligations 194
Long-term Liabilities  (as reported)1,178
Long-term Liabilities  (calculated)1,347
+/- 169
Total Stockholder Equity
Common Stock101,392
Retained Earnings -123,039
Accumulated Other Comprehensive Income 1,235
Capital Surplus 12,909
Total Stockholder Equity (as reported)-7,503
Total Stockholder Equity (calculated)-7,503
+/- 0
Other
Capital Stock101,392
Cash and Short Term Investments 16
Common Stock Shares Outstanding 99,426
Current Deferred Revenue69
Liabilities and Stockholders Equity 701
Net Debt 1,784
Net Invested Capital -5,897
Net Working Capital -6,760
Property Plant and Equipment Gross 2,883
Short Long Term Debt Total 1,800



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-31
> Total Assets 
168
38
2,400
2,451
2,064
6,278
13,147
8,777
21,190
19,033
5,988
6,360
4,996
4,072
10,040
2,993
2,930
572
3,442
2,693
2,486
1,965
8,508
10,646
701
70110,6468,5081,9652,4862,6933,4425722,9302,99310,0404,0724,9966,3605,98819,03321,1908,77713,1476,2782,0642,4512,40038168
   > Total Current Assets 
101
38
1,598
1,665
1,324
3,722
10,797
6,594
19,056
14,957
3,194
3,783
2,983
2,788
9,165
2,969
2,920
568
664
354
353
227
7,222
2,385
266
2662,3857,2222273533546645682,9202,9699,1652,7882,9833,7833,19414,95719,0566,59410,7973,7221,3241,6651,59838101
       Cash And Cash Equivalents 
97
28
995
1,103
519
1,977
5,309
4,030
17,668
11,390
1,162
488
570
367
7,800
2,775
2,337
516
214
41
106
71
6,597
1,725
16
161,7256,59771106412145162,3372,7757,8003675704881,16211,39017,6684,0305,3091,9775191,1039952897
       Short-term Investments 
0
0
0
0
0
0
0
0
0
404
0
88
1,397
1,642
811
0
0
0
0
0
0
0
0
0
0
00000000008111,6421,397880404000000000
       Net Receivables 
4
10
20
524
16
1,115
4,592
2,248
800
2,646
780
662
207
145
387
135
517
23
87
56
45
22
170
127
31
3112717022455687235171353871452076627802,6468002,2484,5921,1151652420104
       Other Current Assets 
0
194
583
0
746
463
665
315
588
518
1,252
2,545
810
635
167
59
66
29
264
172
91
46
100
125
124
12412510046911722642966591676358102,5451,25251858831566546374605831940
   > Long-term Assets 
67
362
802
0
740
2,555
2,350
2,183
2,135
4,075
2,794
2,577
2,012
1,284
875
24
10
5
2,778
2,339
2,133
1,738
1,285
8,261
434
4348,2611,2851,7382,1332,3392,778510248751,2842,0122,5772,7944,0752,1352,1832,3502,555740080236267
       Property Plant Equipment 
67
362
686
695
666
883
913
1,077
1,412
3,671
2,794
2,577
1,927
1,270
862
24
10
5
1,622
1,275
1,069
1,044
1,260
872
434
4348721,2601,0441,0691,2751,622510248621,2701,9272,5772,7943,6711,4121,07791388366669568636267
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,039
1,039
1,039
0
0
7,364
0
07,364001,0391,0391,039000000000000000000
       Intangible Assets 
0
0
116
91
74
1,673
1,436
1,106
723
404
0
0
0
0
13
0
0
0
0
0
0
0
0
0
0
00000000001300004047231,1061,4361,673749111600
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
117
25
25
694
25
25
0
025256942525117000000000000000000
> Total Liabilities 
3
3
81
160
349
538
5,456
2,847
1,651
5,222
4,259
3,869
4,908
4,394
4,969
1,250
776
2,344
8,170
5,709
7,323
6,456
9,741
7,884
8,204
8,2047,8849,7416,4567,3235,7098,1702,3447761,2504,9694,3944,9083,8694,2595,2221,6512,8475,4565383491608133
   > Total Current Liabilities 
3
3
81
160
349
538
5,254
2,758
1,651
3,524
3,479
1,196
1,122
885
1,108
1,250
776
2,343
6,334
3,569
5,516
4,219
5,585
4,745
7,026
7,0264,7455,5854,2195,5163,5696,3342,3437761,2501,1088851,1221,1963,4793,5241,6512,7585,2545383491608133
       Short-term Debt 
0
0
0
0
0
0
103
120
88
592
872
79
89
46
453
261
0
1,321
2,552
454
1,905
1,287
2,604
580
1,224
1,2245802,6041,2871,9054542,5521,321026145346897987259288120103000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
967
2,552
454
1,905
1,134
2,419
358
1,030
1,0303582,4191,1341,9054542,55296700000000000000000
       Accounts payable 
3
3
81
0
160
518
1,108
801
1,563
1,716
0
0
301
397
392
350
333
547
2,538
2,166
2,035
1,353
1,253
735
2,821
2,8217351,2531,3532,0352,1662,538547333350392397301001,7161,5638011,10851816008133
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
2,594
1,107
709
441
241
639
440
475
1,244
949
1,526
1,579
1,503
3,235
2,912
2,9123,2351,5031,5791,5269491,2444754406392414417091,1072,5940000000000
   > Long-term Liabilities 
3
3
81
0
349
538
201
88
1,651
1,699
780
2,674
3,786
3,509
3,861
612
336
1
1,835
2,140
1,807
2,237
4,156
3,140
1,178
1,1783,1404,1562,2371,8072,1401,83513366123,8613,5093,7862,6747801,6991,6518820153834908133
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
471
1,130
954
1,173
967
776
576
5767769671,1739541,130471000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1,364
1,010
487
1,065
3,189
2,363
0
02,3633,1891,0654871,0101,364100000000000000000
> Total Stockholder Equity
165
35
2,319
0
1,715
5,740
7,692
5,930
19,540
13,810
1,730
2,490
88
-322
5,071
1,743
2,154
-1,772
-4,728
-3,016
-4,837
-4,491
-1,233
2,762
-7,503
-7,5032,762-1,233-4,491-4,837-3,016-4,728-1,7722,1541,7435,071-322882,4901,73013,81019,5405,9307,6925,7401,71502,31935165
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
68,830
71,042
75,310
77,006
80,283
89,333
100,521
101,392
101,392100,52189,33380,28377,00675,31071,04268,83000000000000000000
   Retained Earnings -123,039-111,624-104,140-97,276-93,603-89,659-86,712-81,037-71,571-70,823-66,346-59,696-56,920-49,769-38,225-33,675-20,345-12,725-9,735-4,693-3,648-2,864-1,493-154-9
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,637
10,029
10,455
11,197
12,269
12,559
12,909
12,90912,55912,26911,19710,45510,0299,637000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
175
189
3,943
0
5,363
10,268
16,655
19,983
41,543
49,526
42,286
55,644
61,331
59,437
71,475
72,565
73,694
77,960
80,679
85,338
10,455
11,197
12,269
12,559
12,909
12,90912,55912,26911,19710,45585,33880,67977,96073,69472,56571,47559,43761,33155,64442,28649,52641,54319,98316,65510,2685,36303,943189175



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,882
Cost of Revenue-2,872
Gross Profit1010
 
Operating Income (+$)
Gross Profit10
Operating Expense-7,491
Operating Income-4,609-7,481
 
Operating Expense (+$)
Research Development96
Selling General Administrative4,118
Selling And Marketing Expenses-
Operating Expense7,4914,214
 
Net Interest Income (+$)
Interest Income-
Interest Expense-325
Other Finance Cost-65
Net Interest Income-390
 
Pretax Income (+$)
Operating Income-4,609
Net Interest Income-390
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-12,5332,926
EBIT - interestExpense = -325
-12,533
-12,208
Interest Expense325
Earnings Before Interest and Taxes (EBIT)--12,208
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-12,533
Tax Provision-0
Net Income From Continuing Ops-12,533-12,533
Net Income-12,533
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-7,534390
 

Technical Analysis of StageZero Life Sciences Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of StageZero Life Sciences Ltd. The general trend of StageZero Life Sciences Ltd is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine StageZero Life Sciences Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of StageZero Life Sciences Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.04 < 0.05 < 0.05.

The bearish price targets are: 0.04 > 0.04 > 0.04.

Tweet this
StageZero Life Sciences Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of StageZero Life Sciences Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

StageZero Life Sciences Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of StageZero Life Sciences Ltd. The current macd is -0.00187307.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the StageZero Life Sciences Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for StageZero Life Sciences Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the StageZero Life Sciences Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
StageZero Life Sciences Ltd Daily Moving Average Convergence/Divergence (MACD) ChartStageZero Life Sciences Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of StageZero Life Sciences Ltd. The current adx is 12.49.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy StageZero Life Sciences Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
StageZero Life Sciences Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of StageZero Life Sciences Ltd. The current sar is 0.05569433.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
StageZero Life Sciences Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of StageZero Life Sciences Ltd. The current rsi is 42.22. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
StageZero Life Sciences Ltd Daily Relative Strength Index (RSI) ChartStageZero Life Sciences Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of StageZero Life Sciences Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the StageZero Life Sciences Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
StageZero Life Sciences Ltd Daily Stochastic Oscillator ChartStageZero Life Sciences Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of StageZero Life Sciences Ltd. The current cci is -54.64480874.

StageZero Life Sciences Ltd Daily Commodity Channel Index (CCI) ChartStageZero Life Sciences Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of StageZero Life Sciences Ltd. The current cmo is -24.83276239.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
StageZero Life Sciences Ltd Daily Chande Momentum Oscillator (CMO) ChartStageZero Life Sciences Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of StageZero Life Sciences Ltd. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
StageZero Life Sciences Ltd Daily Williams %R ChartStageZero Life Sciences Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of StageZero Life Sciences Ltd.

StageZero Life Sciences Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of StageZero Life Sciences Ltd. The current atr is 0.00193368.

StageZero Life Sciences Ltd Daily Average True Range (ATR) ChartStageZero Life Sciences Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of StageZero Life Sciences Ltd. The current obv is 1,243,900.

StageZero Life Sciences Ltd Daily On-Balance Volume (OBV) ChartStageZero Life Sciences Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of StageZero Life Sciences Ltd. The current mfi is 82.04.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
StageZero Life Sciences Ltd Daily Money Flow Index (MFI) ChartStageZero Life Sciences Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for StageZero Life Sciences Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-28ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside

6.3. Candlestick Patterns

StageZero Life Sciences Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of StageZero Life Sciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.221
Ma 20Greater thanMa 500.044
Ma 50Greater thanMa 1000.044
Ma 100Greater thanMa 2000.046
OpenGreater thanClose0.040
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of StageZero Life Sciences Ltd with someone you think should read this too:
  • Are you bullish or bearish on StageZero Life Sciences Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about StageZero Life Sciences Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about StageZero Life Sciences Ltd

I send you an email if I find something interesting about StageZero Life Sciences Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about StageZero Life Sciences Ltd.

Receive notifications about StageZero Life Sciences Ltd in your mailbox!